Mary Caffrey

The results suggest employers can make a different in health costs through a 2-step process: using testing to identify those at risk, and following up with evidence-based programs of lifestyle change and support.

During remarks at the National Comprehensive Cancer Network Policy Conference, FDA Commissioner Scott Gottlieb, MD, called for more data sharing and explained how the FDA is working to modernize the clinical trial process.

The guidance from the American College of Physicians continues to drive debate on how to care for adults with diabetes.

Lessons from the first meeting of The American Journal of Managed Care® Population Health Council.

AJMC® Convenes First Gathering of Institute for Value-Based Medicine to Share Best Practices in New Payment Models in Cancer Care

The survey found that the real cost of living with diabetes goes beyond what people spend out of pocket, and includes the toll the disease takes on relationships, work, and outside interests.

The authors say there has been a recent uptick in hosptial admissions from hypoglycemic events, and that a therapy to address this is needed.

Health plans are under scrutiny to address social determinants of health, which include food insecurity and poor housing.

The ban on letting people in Medicare connect their continuous glucose monitor (CGM) to a smartphone drew ire from patients, advocates, and even the Government Accountability Office.

Nearly two-thirds of those participating in the study reported feelings of stigma from having to manage type 1 diabetes.

David O. Barbe, MD, MHA, president of the American Medical Association (AMA), made his remarks as private funders are stepping up support for research on gun violence.

The authors speculated that some cancer regimens, such as those with corticosteroids, cause hyperglycemia.

Researchers are examining combination therapies with immunotherapy, with and without chemotherapy.

FDA has fast-tracked the Biologics License Application for cemiplimab, with a decision expected October 28, 2018.

Regeneron's Matthew Fury, MD, said the decision to move immediately to a phase 3 trial came after 2 of 3 patients in a phase 1 trial showed durable responses.

Public health messaging has typically focused on the volume of walking not the intensity. This study suggests for those with limited time, a faster pace could make a difference.

The top status comes as digital providers, such as Omada Health, are trying to convince CMS to include them in the Medicare National Diabetes Prevention Program program.

The results support other evidence that suggests the link between irregular eating patterns and diabetes is distinctly different from the one that drives obesity.

Clinical trial data has shown that the drug helped 28.6% of patients achieve glycated hemoglobin of 7.0% of less by week 24 without severe hypoglycemia or diabetic ketoacidosis and also helped participants lose weight.

Data from the Mayo Clinic suggest that smokers who have quit longer than 15 years may need to be screened for lung cancer, yet they fall outside the window recommended by the United States Preventive Services Task Force.

Researchers based at the University of Michigan compared patients admitted to the intensive care unit (ICU) in Medicaid expansion states with those in nonexpansion states, focusing on 18 specific conditions identified as severe illnesses that could be avoided through better preventive care.

From smartphones to smart rescue inhalers, researchers offered ideas to make chronic obstructive pulmonary disease care more data-driven and personalized.

Navigating FDA's rules to get a fixed-dose combination therapy for chronic obstructive pulmonary disease approved required a large study and a specific population.

Two scientists taking part in a session on addiction and pulmonary health outlined existing evidence about marijuana's effects on chronic obstructive pulmonary disease, emphysema, chronic bronchitis, and cancer. But one speaker warned there are too few longitudinal studies in this area.

Results presented at the American Thoracic Society 2018 International Conference confirm a hypothesis about the connections among pollution, inflammation, and oxidative stress.

A session at the American Thoracic Society 2018 International Conference examined the factors that contribute to disparities and potential partnerships between doctors and lawyers on behalf of patients.

Harvard healthcare economist Michael E. Chernew, PhD, who is co-editor in chief of The American Journal of Managed Care®, discusses elements of the Trump administration proposal to control drug prices.

Officials with GlaxoSmithKline said COLUMBA is the first long-term study for an anti-IL5 biologic to treat severe asthma that has been reported.

Attendees at the American Thoracic Society 2018 International Conference, meeting in San Diego, California, heard details that led to FDA's recent expansion of the indication for GlaxoSmithKline's Trelegy Ellipta, including findings that the once-daily combination also provides significant mortality benefits over a dual therapy that is often the combination patients with chronic obstructive pulmonary disease (COPD) are taking when triple therapy is recommended.

The study comes as FDA is moving to bring more order to the area of mobile health. It is in the midst of a pilot for a precertifcation process that involves well-known companies such as Apple, Verily, and diabetes-specific companies like Tidepool.